{"id":"live-attenuated-influenza-virus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Runny nose"},{"rate":null,"effect":"Sore throat"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Muscle aches"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live influenza virus strains that have been attenuated (weakened) through laboratory passage to reduce virulence while maintaining immunogenicity. Upon intranasal administration, the attenuated virus replicates in the upper respiratory epithelium, triggering both mucosal and systemic immune responses including antibody production and T-cell activation. This approach mimics natural infection while avoiding the complications of wild-type influenza.","oneSentence":"Live attenuated influenza virus vaccine stimulates immune responses by delivering weakened virus that replicates in the respiratory tract without causing severe disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:11.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in pediatric and adult populations"}]},"trialDetails":[{"nctId":"NCT04901455","phase":"EARLY_PHASE1","title":"Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-03","conditions":"COPD","enrollment":24},{"nctId":"NCT04960397","phase":"PHASE1","title":"Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-10","conditions":"H3N2 Influenza","enrollment":140},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT06841913","phase":"PHASE4","title":"Woodsmoke Exposure, Influenza Infection, and Nasal Immunity","status":"SUSPENDED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-10-01","conditions":"Smoke Exposure, Influenza","enrollment":112},{"nctId":"NCT06620185","phase":"NA","title":"GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2025-04-16","conditions":"Influenza","enrollment":36},{"nctId":"NCT06280144","phase":"PHASE4","title":"Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2023-09-22","conditions":"Influenza Prevention","enrollment":6080},{"nctId":"NCT06208683","phase":"PHASE4","title":"The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-11-04","conditions":"Mumps, Influenza","enrollment":400},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT05284851","phase":"PHASE2","title":"The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2022-04-01","conditions":"Influenza Prevention","enrollment":2520},{"nctId":"NCT04110366","phase":"NA","title":"Nasal and Systemic Immune Responses to Nasal Influenza Vaccine","status":"COMPLETED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2018-06-14","conditions":"Influenza, Vaccine Virus Shedding","enrollment":48},{"nctId":"NCT03553940","phase":"PHASE1","title":"H3N2 M2SR in Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-15","conditions":"Influenza, Influenza Immunisation","enrollment":43},{"nctId":"NCT03023683","phase":"PHASE4","title":"Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-10","conditions":"Influenza","enrollment":18},{"nctId":"NCT00461981","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Immune Responses of FluMist®","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2007-05","conditions":"Influenza Vaccine","enrollment":101},{"nctId":"NCT04809389","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-03-29","conditions":"Covid19","enrollment":115},{"nctId":"NCT05056519","phase":"PHASE1","title":"The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2021-09-20","conditions":"Influenza Prevention","enrollment":160},{"nctId":"NCT02559505","phase":"NA","title":"Influenza Immunity in Children","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-10","conditions":"Influenza","enrollment":134},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT04146623","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2019-05-07","conditions":"Influenza","enrollment":33},{"nctId":"NCT03453801","phase":"PHASE1","title":"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-09-30","conditions":"Influenza, Healthy","enrollment":80},{"nctId":"NCT02251288","phase":"PHASE1","title":"A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-05-18","conditions":"Avian Influenza, Immunisation","enrollment":62},{"nctId":"NCT03581903","phase":"PHASE1","title":"A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-09-19","conditions":"Influenza","enrollment":20},{"nctId":"NCT02153671","phase":"PHASE2","title":"Immunogenicity of H5N1 Vaccine Following H5N2","status":"COMPLETED","sponsor":"PATH","startDate":"2014-05","conditions":"Influenza Vaccine","enrollment":43},{"nctId":"NCT03028974","phase":"PHASE4","title":"Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-09-17","conditions":"Influenza","enrollment":77},{"nctId":"NCT02957656","phase":"PHASE1","title":"Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12","conditions":"Influenza A Virus, H7N9 Subtype","enrollment":53},{"nctId":"NCT02133781","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-07","conditions":"Influenza","enrollment":51},{"nctId":"NCT03020498","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":91},{"nctId":"NCT02883426","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09","conditions":"Influenza","enrollment":1},{"nctId":"NCT02250274","phase":"PHASE4","title":"Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2014-09","conditions":"Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection","enrollment":131},{"nctId":"NCT02019745","phase":"","title":"Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2014-06","conditions":"Influenza, Human, Smoking, Respiratory Tract Infections","enrollment":62},{"nctId":"NCT02950688","phase":"PHASE1","title":"Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza, Human","enrollment":""},{"nctId":"NCT02964065","phase":"PHASE3","title":"A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2016-11","conditions":"Influenza","enrollment":9000},{"nctId":"NCT03028987","phase":"PHASE4","title":"Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)","status":"TERMINATED","sponsor":"Stanford University","startDate":"2014-11-19","conditions":"Influenza","enrollment":10},{"nctId":"NCT00344305","phase":"PHASE2","title":"A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2006-05-01","conditions":"Healthy","enrollment":200},{"nctId":"NCT03022435","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-10","conditions":"Influenza","enrollment":22},{"nctId":"NCT01987349","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Influenza","enrollment":72},{"nctId":"NCT03023709","phase":"PHASE4","title":"Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)","status":"TERMINATED","sponsor":"Stanford University","startDate":"2015-09","conditions":"Influenza","enrollment":3},{"nctId":"NCT03023553","phase":"PHASE4","title":"The Human Mucosal Immune Responses to Influenza Virus (SLVP026)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-12","conditions":"Influenza","enrollment":13},{"nctId":"NCT02274545","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-10","conditions":"Influenza A Virus, H7N9 Subtype","enrollment":24},{"nctId":"NCT00729001","phase":"PHASE2","title":"Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-11","conditions":"Infections, Rotavirus","enrollment":529},{"nctId":"NCT01995695","phase":"PHASE1","title":"Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-10","conditions":"Influenza A Virus, H7N9 Subtype","enrollment":48},{"nctId":"NCT01055184","phase":"PHASE1, PHASE2","title":"Effects of Age on Response to the 2009 H1N1 Virus Vaccine","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-03","conditions":"2009 H1N1 Influenza Virus","enrollment":34},{"nctId":"NCT01924208","phase":"PHASE3","title":"Tonsillar Cytokine Expression After Allergen and/or Virus Intervention","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2013-10","conditions":"Healthy","enrollment":180},{"nctId":"NCT01674205","phase":"PHASE1","title":"Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09","conditions":"Influenza, Human","enrollment":36},{"nctId":"NCT00617110","phase":"NA","title":"Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-01","conditions":"Allergic Rhinitis","enrollment":54},{"nctId":"NCT01625689","phase":"PHASE2","title":"Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine","status":"COMPLETED","sponsor":"PATH Vaccine Solutions","startDate":"2012-06","conditions":"Influenza","enrollment":309},{"nctId":"NCT00448617","phase":"","title":"Cigarette Smoke and Susceptibility to Influenza Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2006-07","conditions":"Healthy","enrollment":138},{"nctId":"NCT00516035","phase":"PHASE1","title":"Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-09","conditions":"Influenza, Virus Diseases","enrollment":22},{"nctId":"NCT02151344","phase":"PHASE1","title":"Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-05","conditions":"Influenza A Virus, H7N9 Subtype","enrollment":100},{"nctId":"NCT01181323","phase":"PHASE2","title":"Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Influenza","enrollment":240},{"nctId":"NCT00133523","phase":"PHASE4","title":"FLU-VACS Comparative Study in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-10","conditions":"Influenza","enrollment":2349},{"nctId":"NCT01885169","phase":"","title":"LAIV (Flumist®) Administration in CF Patients","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2013-08","conditions":"Cystic Fibrosis","enrollment":170},{"nctId":"NCT01269723","phase":"NA","title":"Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-12","conditions":"Smoking","enrollment":51},{"nctId":"NCT01369862","phase":"PHASE1, PHASE2","title":"Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2011-01","conditions":"Influenza, Human","enrollment":80},{"nctId":"NCT01044095","phase":"NA","title":"Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2009-11","conditions":"Influenza","enrollment":26},{"nctId":"NCT00922259","phase":"PHASE1","title":"Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-07","conditions":"Influenza A","enrollment":25},{"nctId":"NCT01175122","phase":"PHASE1","title":"Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Influenza A Virus Infection","enrollment":20},{"nctId":"NCT00853255","phase":"PHASE1","title":"Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-07","conditions":"Influenza, Virus Diseases","enrollment":20},{"nctId":"NCT00192413","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-03","conditions":"Influenza","enrollment":3009},{"nctId":"NCT00192309","phase":"PHASE2","title":"Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":31},{"nctId":"NCT00224783","phase":"PHASE1","title":"Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-08","conditions":"Healthy Japanese Male Adults","enrollment":45},{"nctId":"NCT01091246","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-03","conditions":"Healthy or Stable Chronic Illness","enrollment":2312},{"nctId":"NCT00945893","phase":"PHASE4","title":"A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":"Healthy","enrollment":300},{"nctId":"NCT00946101","phase":"PHASE4","title":"A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":"Influenza","enrollment":326},{"nctId":"NCT01078701","phase":"PHASE2","title":"Dose Finding Study of Single Dose GHB11L1 in Healthy Adults","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2009-12","conditions":"Influenza, Human","enrollment":49},{"nctId":"NCT00724997","phase":"PHASE1","title":"Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2007-03","conditions":"Seasonal Human Influenza","enrollment":48},{"nctId":"NCT00734175","phase":"PHASE1","title":"Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-09","conditions":"Influenza, Virus Diseases","enrollment":22},{"nctId":"NCT00192166","phase":"PHASE2","title":"Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-10","conditions":"Influenza","enrollment":1200},{"nctId":"NCT00722774","phase":"PHASE1","title":"Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza, Virus Diseases","enrollment":22},{"nctId":"NCT00110279","phase":"PHASE1","title":"Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-06","conditions":"Influenza, Virus Diseases","enrollment":30},{"nctId":"NCT00347672","phase":"PHASE1","title":"Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"Influenza, Virus Diseases","enrollment":42},{"nctId":"NCT00380237","phase":"PHASE1","title":"Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Influenza, Virus Diseases","enrollment":20},{"nctId":"NCT00488046","phase":"PHASE1","title":"Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-06","conditions":"Influenza, Virus Diseases","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":204,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Live attenuated influenza virus","genericName":"Live attenuated influenza virus","companyName":"Turku University Hospital","companyId":"turku-university-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Live attenuated influenza virus vaccine stimulates immune responses by delivering weakened virus that replicates in the respiratory tract without causing severe disease. Used for Influenza prevention in pediatric and adult populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}